NMNAT1 Antibody (YA8263)

Cat. No.: HY-P88579: Data Sheet User Guide for Antibodies
FAQs
Technical Support

NMNAT1 Antibody (YA8263) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to NMNAT1.

For research use only. We do not sell to patients.

Size	Price	Stock
20 μL		Ask For Quote & Lead Time
50 μL		Ask For Quote & Lead Time
100 μL		Ask For Quote & Lead Time

* Please select Quantity before adding items.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Documentation

Description

NMNAT1 Antibody (YA8263) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to NMNAT1.

Host

Mouse

Clonality

Monoclonal

Molecular Weight

Predicted band size: 31.8 kDa

Species Reactivity

Human

SwissProt ID

Q9HAN9

Immunogen

Full length human recombinant protein of human NMNAT1 produced in HEK293T cell.

Application &
Dilution Ratio

Application	Dilution Ratio
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:150-500
FC FC: Flow Cytometry	1:100

Sensitivity	Endogenous	Purity	Affinity purified
Conjugation	Non-conjugated	Modification	Unmodified
Isotype	IgG1

Appearance

Liquid

Formulation

Spplied in PBS (pH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Background

Function：Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP (PubMed:17402747). Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate with the same efficiency (PubMed:17402747). Can use triazofurin monophosphate (TrMP) as substrate (PubMed:17402747). Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+) (PubMed:17402747). For the pyrophosphorolytic activity, prefers NAD(+) and NaAD as substrates and degrades NADH, nicotinic acid adenine dinucleotide phosphate (NHD) and nicotinamide guanine dinucleotide (NGD) less effectively (PubMed:17402747). Involved in the synthesis of ATP in the nucleus, together with PARP1, PARG and NUDT5 (PubMed:27257257). Nuclear ATP generation is required for extensive chromatin remodeling events that are energy-consuming (PubMed:27257257). Also acts as a cofactor for glutamate and aspartate ADP-ribosylation by directing PARP1 catalytic activity to glutamate and aspartate residues on histones (By similarity). Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+) (PubMed:17402747). Protects against axonal degeneration following mechanical or toxic insults (By similarity). Neural protection does not correlate with cellular NAD(+) levels but may still require enzyme activity (By similarity)

Subcellular Localization：Nucleus

Expression：
Tissue_Specificity: Widely expressed with highest levels in skeletal muscle, heart and kidney. Also expressed in the liver pancreas and placenta. Widely expressed throughout the brain

Isoforms & Post-Translational Modification：Q9HAN9: 279 amino acids, molecular weight 31932 Da.

Subunit：Homohexamer (PubMed:11751893)

Synonyms

LCA9; NMNAT; PNAT1; SHILCA

Documentation

User Guide for Antibodies (1077 KB)